Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons

Brain

Volumn 137, Issue 8, 2014, Pages 2287-2302

  Dragicevic, Elena ^a   Poetschke, Christina ^a   Duda, Johanna ^a   Schlaudraff, Falk ^a   Lammel, Stephan ^b   Schiemann, Julia ^c   Fauler, Michael ^a   Hetzel, Andrea ^d   Watanabe, Masahiko ^e   Lujan, Rafael ^f   Malenka, Robert C ^b   Striessnig, Joerg ^g   Liss, Birgit ^a  

^a UNIVERSITY OF ULM   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^e HOKKAIDO UNIVERSITY   (Japan)

^f Universidad Castilla La Mancha   (Spain)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

cocaine; D2 autoreceptor; isradipine; l DOPA; Parkinsons disease

Indexed keywords

CALCIUM CHANNEL L TYPE; COCAINE; DOPAMINE 2 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LEVODOPA; MESSENGER RNA; NEURONAL CALCIUM SENSOR; POTASSIUM CHANNEL; ALPHA1D (CAV1.3) L TYPE CALCIUM CHANNEL, HUMAN; ALPHA1D (CAV1.3) L-TYPE CALCIUM CHANNEL, HUMAN; AUTORECEPTOR; CACNA1D PROTEIN, MOUSE; FREQUENIN CALCIUM SENSOR PROTEINS; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; ISRADIPINE; KCNJ6 PROTEIN, HUMAN; NEUROPEPTIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN SLICE; CELL MATURATION; CONTROLLED STUDY; DESENSITIZATION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ELECTROPHYSIOLOGICAL PROCEDURES; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEGATIVE FEEDBACK; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ANIMAL; C57BL MOUSE; CALCIUM SIGNALING; CYTOLOGY; D2-AUTORECEPTOR; KNOCKOUT MOUSE; L-DOPA; METABOLISM; PATHOLOGY; PHYSIOLOGY;

COCAINE; D2-AUTORECEPTOR; ISRADIPINE; L-DOPA; PARKINSONS DISEASE;

ANIMALS; AUTORECEPTORS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; DOPAMINERGIC NEURONS; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONAL CALCIUM-SENSOR PROTEINS; NEUROPEPTIDES; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA;

EID: 84904977585     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu131     Document Type: Article

References (71)

1. Aguado C, Colon J, Ciruela F, Schlaudraff F, Cabanero MJ, Perry C, et al. Cell type-specific subunit composition of G protein-gated potassium channels in the cerebellum. J Neurochem 2008; 105: 497-511.
2. Anzalone A, Lizardi-Ortiz JE, Ramos M, De Mei C, Hopf FW, Iaccarino C, et al. Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. J Neurosci 2012; 32: 9023-34.
3. Bean BP. Neurophysiology: Stressful pacemaking. Nature 2007; 447: 1059-60.
4. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182-217.
5. Beckstead MJ, Ford CP, Phillips PE, Williams JT. Presynaptic regulation of dendrodendritic dopamine transmission. Eur J Neurosci 2007; 26: 1479-88.
6. Beckstead MJ, Williams JT. Long-term depression of a dopamine IPSC. J Neurosci 2007; 27: 2074-80.
7. Bello EP, Mateo Y, Gelman DM, Noain D, Shin JH, Low MJ, et al. Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2-Autoreceptors. Nat Neurosci 2011; 14: 1033-8.
8. Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: An update. Trends Neurosci 2007; 30: 194-202.
9. Callaghan RC, Cunningham JK, Sykes J, Kish SJ. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug and alcohol dependence 2012; 120: 35-40.
10. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007; 447: 1081-6.
11. Collier TJ, Kanaan NM, Kordower JH. Ageing as a primary risk factor for Parkinson's disease: Evidence from studies of non-human primates. Nat Rev Neurosci 2011; 12: 359-66.
12. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009; 30: 379-87.
13. Drion G, Massotte L, Sepulchre R, Seutin V. How modeling can reconcile apparently discrepant experimental results: The case of pacemaking in dopaminergic neurons. PLoS Comput Biol 2011; 7: E1002050.
14. Ford CP. The role of D2-Autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience 2014; 23: Pii: S0306-4522 (14)00037-2.
15. Ford CP, Gantz SC, Phillips PE, Williams JT. Control of extracellular dopamine at dendrite and axon terminals. J Neurosci 2010; 30: 6975-83.
16. Gantz SC, Bunzow JR, Williams JT. Spontaneous inhibitory synaptic currents mediated by a G protein-coupled receptor. Neuron 2013; 78: 807-12.
17. Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov Disord 2011; 26: 1042-8.
18. Gazewood JD, Richards DR, Clebak K. Parkinson disease: An update. Am Fam Physician 2013; 87: 267-73.
19. Ginovart N, Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 2012; 212: 27-52.
20. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005; 45: 489-96.
21. Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: The DARPP-32/protein phosphatase-1 cascade. Neuron 1999; 23: 435-47.
22. Grundemann J, Schlaudraff F, Liss B. UV-laser microdissection and mRNA expression analysis of individual neurons from postmortem Parkinson's disease brains. Methods Mol Biol 2011; 755: 363-74.
23. Guzman JN, Sanchez-Padilla J, Chan CS, Surmeier DJ. Robust pacemaking in SN Da neurons. J Neurosci 2009; 29: 11011-9.
24. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010; 468: 696-700.
25. Hamasaki-Katagiri N, Ames JB. Neuronal calcium sensor-1 (Ncs1p) is upregulated by calcineurin to promote Ca2 + tolerance in fission yeast. J Biol Chem 2010; 285: 4405-14.
26. Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, et al. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2 + currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci 2000; 20: 8987-95.
27. Hurley MJ, Brandon B, Gentleman SM, Dexter DT. Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 2013; 136 (Pt 7): 2077-97.
28. Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 2011; 43: 364-71.
29. Jo J, Heon S, Kim MJ, Son GH, Park Y, Henley JM, et al. Metabotropic glutamate receptor-mediated LTD involves two interacting Ca(2 + ) sensors, NCS-1 and PICK1. Neuron 2008; 60: 1095-111.
30. Kabbani N, Negyessy L, Lin R, Goldman-Rakic P, Levenson R. Interaction with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine receptor. J Neurosci 2002; 22: 8476-86.
31. Khaliq ZM, Bean BP. Pacemaking in dopaminergic ventral tegmental area neurons: Depolarizing drive from background and voltage-dependent sodium conductances. J Neurosci 2010; 30: 7401-13.
32. Koyrakh L, Lujan R, Colon J, Karschin C, Kurachi Y, Karschin A, et al. Molecular and cellular diversity of neuronal G-protein-gated potassium channels. J Neurosci 2005; 25: 11468-78.
33. Lammel S, Hetzel A, Hackel O, Jones I, Liss B, Roeper J. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 2008; 57: 760-73.
34. Lammel S, Ion DI, Roeper J, Malenka RC. Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron 2011; 70: 855-62.
35. Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA. The 'motor complication syndrome'in rats with 6-OHDA lesions treated chronically with L-DOPA: Relation to dose and route of administration. Behav Brain Res 2007; 177: 150-9.
36. Liss B, Roeper J. Correlating function and gene expression of individual basal ganglia neurons. Trends Neurosci 2004; 27: 475-81.
37. Liss B, Roeper J. Ion channels and regulation of dopamine neuron activity. In: Iversen LL, Iversen SDI, Dunnett SB, Björklund A, editors. Dopamine handbook. Oxford, UK: Oxford University press; 2010. p. 118-38.
38. Lundblad M, Picconi B, Lindgren H, Cenci MA. A model of L-DOPAinduced dyskinesia in 6-hydroxydopamine lesioned mice: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004; 16: 110-23.
39. Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 2005; 194: 66-75.
40. Luscher C, Slesinger PA. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat Rev Neurosci 2010; 11: 301-15.
41. Marras C, Gruneir A, Rochon P, Wang X, Anderson G, Brotchie J, et al. Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann Neurol 2012; 71: 362-9.
42. Narushima M, Uchigashima M, Hashimoto K, Watanabe M, Kano M. Depolarization-induced suppression of inhibition mediated by endocannabinoids at synapses from fast-spiking interneurons to medium spiny neurons in the striatum. Eur J Neurosci 2006; 24: 2246-52.
43. Neve KA, Ford CP, Buck DC, Grandy DK, Neve RL, Phillips TJ. Normalizing dopamine D2 receptor-mediated responses in D2 null mutant mice by virus-mediated receptor restoration: Comparing D2 and D2. Neuroscience 2013; 248C: 479-87.
44. Olanow CW, Schapira AH. Therapeutic prospects for Parkinson disease. Ann Neurol 2013; 74: 337-47.
45. Olson PA, Tkatch T, Hernandez-Lopez S, Ulrich S, Ilijic E, Mugnaini E, et al. G-protein-coupled receptor modulation of striatal CaV1.3 L-type Ca2 + channels is dependent on a Shank-binding domain. J Neurosci 2005; 25: 1050-62.
46. Parkinson Study GroupPhase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD) Mov Disord 2013 28 1823-1831
47. Pasternak B, Svanstrom H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol 2012; 175: 627-35.
48. Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova S, Chen H, et al. Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2 + channels. Cell 2000; 102: 89-97.
49. Prinz A, Selesnew LM, Liss B, Roeper J, Carlsson T. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease. Exp Neurol 2013; 248: 236-45.
50. Puopolo M, Raviola E, Bean BP. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J Neurosci 2007; 27: 645-56.
51. Rice ME, Patel JC, Cragg SJ. Dopamine release in the basal ganglia. Neuroscience 2011; 198: 112-37.
52. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 2010; 67: 600-6.
53. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-Administration of cocaine. Science 1987; 237: 1219-23.
54. Saab BJ, Georgiou J, Nath A, Lee FJ, Wang M, Michalon A, et al. NCS-1 in the dentate gyrus promotes exploration, synaptic plasticity, and rapid acquisition of spatial memory. Neuron 2009; 63: 643-56.
55. Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 2003; 37: 577-82.
56. Schultz W. Multiple functions of dopamine neurons. F1000 Biol Rep 2010; 2: 2.
57. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: Genetics and pathogenesis. Annu Rev Pathol 2011; 6: 193-222.
58. Simuni T, Borushko E, Avram MJ, Miskevics S, Martel A, Zadikoff C, et al. Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study. Mov Disord 2010; 25: 2863-6.
59. Sinnegger-Brauns MJ, Hetzenauer A, Huber IG, Renstrom E, Wietzorrek G, Berjukov S, et al. Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by Ltype Ca 2 + channels. J Clin Invest 2004; 113: 1430-9.
60. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, et al. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol 2009; 75: 407-14.
61. Striessnig J, Koschak A. Exploring the function and pharmacotherapeutic potential of voltage-gated Ca2 + channels with gene knockout models. Channels (Austin) 2008; 2: 233-51.
62. Striessnig J, Koschak A, Sinnegger-Brauns MJ, Hetzenauer A, Nguyen NK, Busquet P, et al. Role of voltage-gated L-type Ca2 + channel isoforms for brain function. Biochem Soc Trans 2006; 34 (Pt 5): 903-9.
63. Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord 2013; 28: 715-24.
64. Surmeier DJ, Guzman JN, Sanchez J, Schumacker PT. Physiological phenotype and vulnerability in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2: A009290.
65. Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J Biol Chem 2013; 288: 10736-41.
66. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothos EN, et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci USA 2009; 106: 14622-7.
67. Ungless MA, Grace AA. Are you or aren't you?. Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci 2012; 35: 422-30.
68. Ungless MA, Whistler JL, Malenka RC, Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 2001; 411: 583-7.
69. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000; 408: 199-203.
70. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 24: 125-32.
71. Yamamoto M, Schapira AH. Dopamine agonists in Parkinson's disease. Expert Rev Neurother 2008; 8: 671-7.